Kiromic BioPharma (KRBP) Stock Price, News & Analysis

Company Overview

Kiromic BioPharma is a clinical-stage immuno-oncology company dedicated to advancing natural killer (NK) cell–based therapies for patients with hard-to-treat solid tumors. The company’s approach leverages both ex vivo expanded NK cells and proprietary NK cell engager (NKE) molecules designed to harness the innate immune system against malignancies. Kiromic’s technology platforms aim to enhance tumor targeting, increase persistence of immune effector cells, and overcome common mechanisms of tumor resistance.

The company’s pipeline features a suite of investigational candidates, including KIRO-101, an off-the-shelf NKE program entering early-phase clinical evaluation, and KIRO-109, an ex vivo expanded NK cell product optimized for enhanced cytotoxicity. These programs target multiple solid tumor indications, such as triple-negative breast cancer, pancreatic ductal adenocarcinoma, and colorectal carcinoma. Kiromic also advances preclinical efforts in novel bispecific engager constructs and next-generation cell therapies intended to broaden patient access and improve response rates.

Founded in 2016 and headquartered in Houston, Texas, Kiromic BioPharma went public in 2021 via a business combination transaction and maintains research collaborations with leading cancer centers in North America and Europe. The company has scaled manufacturing capabilities to support both clinical supply and future commercial demands, while pursuing strategic partnerships to augment development resources and accelerate global access to its therapies.

Kiromic’s management team brings together seasoned leaders in oncology research, cell therapy manufacturing, and pharmaceutical development. The company’s scientific advisory board includes experts from top academic institutions, guiding clinical strategy and translational research initiatives. With a focus on innovation and patient impact, Kiromic continues to build on its foundational science to deliver next-generation immunotherapeutic solutions.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.21 to $1.66
• 52-Week Range: N/A
• Volume: 107,749 shs
• Average Volume: 11,347 shs
• Market Capitalization: $330 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

KRBP Stock Analysis - Frequently Asked Questions

How were Kiromic BioPharma's earnings last quarter?

Kiromic BioPharma, Inc. (NASDAQ:KRBP) posted its quarterly earnings data on Friday, November, 8th. The company reported ($0.65) EPS for the quarter.

When did Kiromic BioPharma's stock split?

Kiromic BioPharma shares reverse split on Monday, March 13th 2023.The 1-30 reverse split was announced on Monday, March 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Kiromic BioPharma IPO?

Kiromic BioPharma (KRBP) raised $16 million in an IPO on Friday, October 16th 2020. The company issued 1,200,000 shares at $12.00-$14.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Paulson Investment Company was co-manager.

What other stocks do shareholders of Kiromic BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kiromic BioPharma investors own include Athenex (ATNX), KLX Energy Services (KLXE), Brainstorm Cell Therapeutics (BCLI), NGL Energy Partners (NGL), Orchard Therapeutics (ORTX), TherapeuticsMD (TXMD) and Achilles Therapeutics (ACHL).

Company Calendar

• Last Earnings: 11/08/2024
• Today: 7/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KRBP
• CIK: 1792581
• Web: www.kiromic.com
• Phone: 832-968-4888
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.90 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -277.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.16
• Quick Ratio: 0.22

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($8.29) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,571,000
• Free Float: 1,217,000
• Market Cap: $330 thousand
• Optionable: Not Optionable
• Beta: 1.66